Download PDF
Pharmacopsychiatry 2003; 36: 102-106
DOI: 10.1055/s-2003-43053
Original Paper
© Georg Thieme Verlag Stuttgart · New York

24S-Hydroxycholesterol: a Marker of Brain Cholesterol Metabolism

D. Lütjohann1 , K. von Bergmann1
  • 1Department of Clinical Pharmacology, University of Bonn
Further Information

Publication History

Publication Date:
22 October 2003 (online)

Also available at
    Permissions and Reprints

The enzymatic conversion of CNS cholesterol to 24S-hydroxycholesterol, which readily crosses the blood-brain barrier, is the major pathway for brain cholesterol elimination and brain cholesterol homeostasis maintenance. The enzyme mediating this conversion has been characterized at the molecular level (CYP46) and is mainly located in neurons. Like other oxysterols, 24S-hydroxycholesterol is efficiently converted into normal bile acids or excreted in bile in its sulfated and glucuronidated form. Levels of 24S-hydroxycholesterol in the circulation decrease with age in infants and children. In adults, however, the levels appear to be stable. There is accumulating evidence pointing toward a potentially important link between cholesterol, β-amyloid, and Alzheimer's disease. Concentrations of 24S-hydroxycholesterol in plasma and cerebrospinal fluid (CSF) are significantly higher in Alzheimer’s disease and vascular demented patients at early stages of the disease compared to healthy subjects. Variations in genetic background, time of disease onset, and severity of dementia are potential sources of variance. Inhibitors of cholesterol biosynthesis, also termed statins, seem to have a reductive influence on the generation of the amyloid precursor protein, the neuronal secretion of β-amyloid, and on de novo cholesterol synthesis. Recent epidemiological studies indicate that the prevalence of diagnosed AD and vascular dementia is reduced among people taking statins for a longer period of time. High-dose simvastatin treatment (80 mg/day) in patients with hypercholesterolemia leads to a significant decrease in brain-specific serum 24S-hydroxycholesterol concentrations and indicates a diminished cholesterol metabolism in the brain. CSF levels of cholesterol and lathosterol, a cholesterol precursor considered to be an indicator for cholesterol neogenesis, were significantly decreased in statin-treated subjects compared to non-treated normo- and hypercholesterolemic subjects. Also, CSF concentrations of 24S-hydroxycholesterol were significantly lower in statin-treated patients compared to normocholesterolemic subjects. Treatment with high-dose simvastatin in normocholesterolemic Alzheimer patients for 26 weeks at early stages of the disease results in a significant decrease in Aβ-levels in cerebrospinal fluid. This decrease correlates with the reduction of 24S-hydroxycholesterol.

References

  • 1 Babiker A, Diczfalusy U. Transport of side-chain oxidized oxysterols in the human circulation.  Biochim Biophys Acta. 1998;  1392 333-339
    PubMedGoogle Scholar
  • 2 Ball M -J. Neuronal loss, neurofïbrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study.  Acta Neuropathol Berl. 1977;  37 111-118
    CrossrefPubMedGoogle Scholar
  • 3 Björkhem I, Andersson U, Ellis E, Alvelius G, Ellegard L, Diczfalusy U. et al . From brain to bile. Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans.  J Biol Chem. 2001;  276 37 004-37 010
    PubMedGoogle Scholar
  • 4 Björkhem I, Lütjohann D, Breuer O, Sakinis A, Wennmalm A. Importance of a Novel Oxidative Mechanism for Elimination of Brain Cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18Ü2 techniques in vivo and in vitro.  J Biol Chem. 1997;  272 30 178-30 184
    PubMedGoogle Scholar
  • 5 Björkhem I, Lütjohann D, Diczfalusy U, Stable L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation.  J Lipid Res. 1998;  39 1594-1600
    PubMedGoogle Scholar
  • 6 Björkhem I, Miettinen T, Reihner E, Ewerth S, Angelin B, Einarsson K. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver.  J Lipid Res. 1987;  28 1 137-1 143
    PubMedGoogle Scholar
  • 7 Botti R -E, Triscari J, Pan H -Y, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.  Clin Neuropharmacol. 1991;  14 256-261
    PubMedGoogle Scholar
  • 8 Bretillon L, Lütjohann D, Stable L, Widhe T, Bindl L, Eggertsen G. et al . Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface.  J Lipid Res. 2000;  41 840-845
    PubMedGoogle Scholar
  • 9 Dietschy J -M, Turley S -D. Cholesterol metabolism in the brain.  Curr Opin Lipidol. 2001;  12 105-112
    CrossrefPubMedGoogle Scholar
  • 10 Dupuy A -M, Mas E, Ritchie K, Descomps B, Badiou S, Cristol J-P. et al . The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer’s disease.  Gerontology. 2001;  47 213-218
    CrossrefPubMedGoogle Scholar
  • 11 Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P. et al . Simvastatin strongly reduces levels of Alzheimer’s disease beta - amyloid peptìdes Abeta 42 and Abeta 40 in vitro and in vivo.  Proc Natl Acad Sci USA.. 2001;  98 5856-5861
    CrossrefPubMedGoogle Scholar
  • 12 Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S. et al . Effects of statins on cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide.  Neurology. 2002;  59 1257-1258
    PubMedGoogle Scholar
  • 13 Frears E -R, Stephens D -J, Walters C -E, Davies H, Austen B -M. The role of cholesterol in the biosynthesis of beta-amyloid.  Neuroreport. 1999;  10 1699-1705
    PubMedGoogle Scholar
  • 14 Galbete J -L, Martin T -R, Peressini E, Modena P, Bianchi R, Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway.  Biochem J. 2000;  348 307-313
    CrossrefPubMedGoogle Scholar
  • 15 Hartmann T. Cholesterol, A beta and Alzheimer's disease.  Trends Neurosci. 2001;  24 45-48
    CrossrefPubMedGoogle Scholar
  • 16 Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt H -C, Riemenschneider M, De Deyn P -P. et al . Improved discrimination of AD patients using beta-amyloid(l-42) and tau levels in CSF.  Neurology. 1999;  52 1555-1562
    CrossrefPubMedGoogle Scholar
  • 17 Hyman B -T, Van Horsen G -W, Damasio A -R, Barnes C -L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.  Science. 1984;  225 1 168-1 170
    PubMedGoogle Scholar
  • 18 Ignatius M -J, Shooter E -M, Pitas R -E, Mahley R -W. Lipoprotein uptake by neuronal growth cones in vitro.  Science. 1987;  236 959-962
    PubMedGoogle Scholar
  • 19 Tick H, Zornberg G -L, Tick S -S, Seshadri S, Drachman D -A. Statins and the risk of dementia.  Lancet. 2000;  356 1627-1631
    CrossrefPubMedGoogle Scholar
  • 20 Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain.  JNeurochem. 1995;  64 895-901
    PubMedGoogle Scholar
  • 21 Kempen H -J, Glatz J -F, Gevers Leuven J -A, van der Voort H -A, Katan M -B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.  J LipidRes. 1988;  29 1149-1155
    PubMedGoogle Scholar
  • 22 Kivipelto M, Helkala E -L, Laakso M -P, Hanninen T, Hallikainen M, Alhainen K. et al . Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.  BMJ. 2001;  322 1447-1451
    CrossrefPubMedGoogle Scholar
  • 23 Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10.  Proc Natl Acad Sci USA. 2001;  98 5815-5820
    CrossrefPubMedGoogle Scholar
  • 24 Locatelli S, Lütjohann D, Schmidt H -H, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.  Arch Neurol. 2002;  59 213-216
    CrossrefPubMedGoogle Scholar
  • 25 Lund E -G, Guileyardo J -M, Russel D. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain.  Proc Natl Acad Sci USA. 1999;  96 7238-7243
    CrossrefPubMedGoogle Scholar
  • 26 Lütjohann D. Cholesterol Homeostasis in the Brain: Importance of 24S-Hydroxylation. Doctorial Thesis 1999; ISBN 91-628-3410-X
    Google Scholar
  • 27 Lütjohann D, Björkhem I, Locatelli S, Dame C, Schmolling J, von Bergmann K. et al . Cholesterol dynamics in the foetal and neonatal brain as reflected by circulatory levels of 24S-hydroxycholesterol.  ActaPaediatr. 2001;  90 652-657
    PubMedGoogle Scholar
  • 28 Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén A, Diczfalusy U. et al . Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation.  Proc Natl Acad Sci USA. 1996;  93 9799-9804
    CrossrefPubMedGoogle Scholar
  • 29 Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring R -D. et al . Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.  J Lipid Res. 2000;  41 195-198
    PubMedGoogle Scholar
  • 30 Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Diczfalusy U. et al .Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res 2001: 42
    Google Scholar
  • 31 Meaney S, Lütjohann D, Diczfalusy U, Björkhem I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice.  Biochim Biophys Acta. 2000;  1486 293-298
    PubMedGoogle Scholar
  • 32 Notkola I -L, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P. et al . Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease.  Neuroepidemiology. 1998;  17 14-20
    PubMedGoogle Scholar
  • 33 Ose L, Davidson M -H, Stein E -A, Kastelein J -J, Scott R -S, Hunninghake D -B. et al . Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.  Clin Cardiol. 2000;  23 39-46
    PubMedGoogle Scholar
  • 34 Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R. et al . 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.  J Psychiatr Res. 2002;  36 7-32
    CrossrefPubMedGoogle Scholar
  • 35 Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao M. et al . Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease.  Neuroreport. 2000;  11 1959-1962
    PubMedGoogle Scholar
  • 36 Pitas R -E, Boyles J -K, Lee H -E, Foss D, Mahley R -W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins.  Biochim Biophys Acta. 1987;  917 148-161
    PubMedGoogle Scholar
  • 37 Rockwood K, Kirkland S, Hogan D -B, MacKnight C, Merry H, Verreault R. et al . Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.  ArchNeurol. 2002;  59 223-227
    PubMedGoogle Scholar
  • 38 Saunders A -M, Strittmatter W -J, Schmechel D, George-Hyslop P -H, Pericak- Vance M -A, Too S -H. et al . Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease [see comments].  Neurology. 1993;  43 1467-1472
    PubMedGoogle Scholar
  • 39 Schmechel D -E, Saunders A -M, Strittmatter W -J, Grain B -J, Hulette C -M, Too S -H. et al . Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer’s disease.  Proc Natl Acad Sci USA. 1993;  90 9649-9653
    CrossrefPubMedGoogle Scholar
  • 40 Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, Beyreuther K . et al . Cerebrospinal fluid 24S-Hydroxycholesterol is increased in Alzheimer’s disease compared to healthy controls.  Neurosci Letters. 2002;  324 83-85
    CrossrefPubMedGoogle Scholar
  • 41 Selkoe D -J. Alzheimer’s disease: genes, proteins, and therapy.  Physiol Rev. 2001;  81 741-766
    PubMedGoogle Scholar
  • 42 Simons M, Keller P, De Strooper B, Beyreuther K, Dottì C -G, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.  Proc Natl Acad Sci USA. 1998;  95 6460-6464
    CrossrefPubMedGoogle Scholar
  • 43 Simons M, Keller P, Dichgans J, Schulz J -B. Cholesterol and Alzheimer’s disease: is there a link?.  Neurology. 2001;  57 1089-1093
    PubMedGoogle Scholar
  • 44 Simons M, Schwärzler F, Lütjohann D, von Bergmann K, Beyreuther K, Dichgans J. et al . Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double- blind trial.  Ann Neurol. 2002;  52 346-350
    CrossrefPubMedGoogle Scholar
  • 45 Strittmatter W -J, Saunders A -M, Schmechel D, Pericak- Vance M, Enghild J, Salvesen G -S. et al . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease.  Proc Natl Acad Sci USA. 1993;  90 1977-1981
    CrossrefPubMedGoogle Scholar
  • 46 Strittmatter W -J, Saunders A -M, Schmechel D, Pericak- Vance M, Enghild J, Salvesen G -S. et al . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease.  Proc Natl Acad Sci USA. 1993;  90 1977-1981
    CrossrefPubMedGoogle Scholar
  • 47 Theunissen J -J, Jackson R -L, Kempen H -J, Demel R -A. Membrane properties of oxysterols. Interfacial orientation, influence on membrane permeability and redistribution between membranes.  Biochim Biophys Acta. 1986;  860 66-74
    PubMedGoogle Scholar
  • 48 Wolozin B. A fluid connection: Cholesterol and Abeta.  Proc Natl Acad Sci USA. 2001;  98 5371-5373
    CrossrefPubMedGoogle Scholar
  • 49 Wolozin B, Kellman W, Ruosseau P, Celesia G -G, Siegel G. Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.  Arch Neurol. 2000;  57 1439-1443
    CrossrefPubMedGoogle Scholar

Dieter Lütjohann, PhD

Department of Clinical Pharmacology

University of Bonn

Sigmund-Freud Str. 25

53105 Bonn

Germany

Phone: +49-228-2876080

Fax: +49-228-2876094

Email: d.luetjohann@uni-bonn.de

      >